C. Porsbjerg (Copenhagen, Denmark), A. Papi (Ferrara, Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics
N. Pfeifer (South San Francisco, United States of America), T. Guerin (Dublin, Ireland), K. Colley (South San Francisco, United States of America), W. Yates (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), J. Woo (South San Francisco, United States of America), R. Graham (South San Francisco, United States of America), D. Bourdet (South San Francisco, United States of America), D. Singh (Manchester, United Kingdom)
|    |
Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma
H. Chen (South San Francisco, United States of America), R. Kunder (South San Francisco, United States of America), Y. Zou (South San Francisco, United States of America), H. Gugelmann (South San Francisco, United States of America), J. Galanter (South San Francisco, United States of America), R. Zhu (South San Francisco, United States of America), R. Owen (South San Francisco, United States of America), T. Staton (South San Francisco, United States of America), M. Wright (South San Francisco, United States of America), M. Durk (South San Francisco, United States of America), A. Eliahu (South San Francisco, United States of America), M. Wilson (South San Francisco, United States of America), R. Beasley (Wellington, New Zealand), I. Braithwaite (Wellington, New Zealand)
| |
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma
D. Singh (Manchester, United Kingdom), R. Fuhr (Berlin, Germany), N. Bird (Stevenage, United Kingdom), S. Mole (Stevenage, United Kingdom), K. Hardes (Brentford, United Kingdom), Y. Man (Stevenage, United Kingdom), A. Cahn (Stevenage, United Kingdom), S. Yancey (Research Triangle Park, North Carolina, United States of America), I. Pouliquen (Brentford, United Kingdom)
| |
Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR
S. Korn (Mainz, Germany), A. Bourdin (Montpellier, France), G. Chupp (New Haven, United States of America), G. Colice (Gaithersburg, United States of America), C. Ambrose (Gaithersburg, United States of America), K. Kmita (Warsaw, Poland), J. Llanos-Ackert (Thousand Oaks, United States of America), N. Molfino (Thousand Oaks, United States of America), B. Cook (Gaithersburg, United States of America)
| |
Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC)
S. Birring (London, United Kingdom), J. Smith (Manchester, United Kingdom), A. Morice (Hull, United Kingdom), M. Sher (Largo, United States of America), J. Hull (London, United Kingdom), A. Goldsobel (San Jose, United States of America), S. Lanouette (Montreal, Canada), E. Li (Wilmington, United States of America), L. Harvey (Montreal, Canada), C. Bonuccelli (Wilmington, United States of America)
| |
Intravenous iron replacement improves exercise tolerance in COPD: A randomised trial
C. Martin Ontiyuelo (Barcelona, Spain), A. Rodó Pin (Barcelona, Spain), D. Echeverría Esnal (Barcelona, Spain), M. Admetlló (Barcelona, Spain), X. Duran Jordà (Barcelona, Spain), J. Gea (Barcelona, Spain), E. Barreiro (Barcelona, Spain), D. Rodríguez-Chiaradía (Barcelona, Spain)
| |
Durability of Zephyr Valve treatment: 24-month follow-up in the TRANSFORM Study
A. Kirk (Clydebank, United Kingdom), D. Slebos (Groningen, Netherlands), M. Kornaszweska (Cardiff, United Kingdom), P. Shah (London, United Kingdom), K. Carron (Menen, Belgium), H. Mal (Paris, France), C. Pison (Grenoble, France), N. Downer (Sutton-in-Ashfield, United Kingdom), K. Darwiche (Essen, Germany), J. Rao (Sheffield, United Kingdom), R. Hübner (Berlin, Germany), V. Trosini-Desert (Paris, France), R. Eberhardt (Heidelberg, Germany), F. Herth (Heidelberg, Germany), E. Derom (Ghent, Belgium), C. Marquette (Nice, France), N. SHARGILL (Redwood City, CA, United States of America), S. Kemp (London, United Kingdom)
| |
Discussion
| |